Now Available: A Comparison of In Vitro and In Vivo Biomarker Response After Treatment with an Anti-CD3 monoclonal Antibody
September 5, 2012 - Cytokine release syndrome is a potential adverse effect attributed to cellular release of pro-inflammatory cytokines that occurs on initial and sometimes subsequent intravenous infusion of some types of protein biotherapeutics. For this reason, generalized systemic inflammation, whether caused by some biologics due to target activation, as an off-target secondary event or indirectly as a result of tissue damage, has become a growing concern in the pharmaceutical industry. Measurement of biomarkers of inflammation has been shown to be a useful component of non-clinical testing approaches to identify compounds that have the potential to modulate the immune system.
Charles River has validated several assays intended to analyze markers of the inflammatory response in serum and/or plasma. An in vivo study in which animals were stimulated with an anti-CD3 mAb was initiated to demonstrate the sensitivity of the validated method, to characterize the range and dynamics of inflammatory responses after treatment, and to verify if modulation of inflammatory markers can be adequately monitored. Additionally, assays were developed to identify the potential of compounds to induce cytokine release in vitro. The development of reliable in vitro assays capable of predicting in vivo cytokine release could help reduce study costs and the number of animals used for drug screening purposes.
The sensitivity of the assays was shown to be appropriate to measure in vivo changes in inflammation markers. In vitro stimulation may be predictive of the intensity of cytokine release, but in vivo and in vitro stimulation differ in the magnitude and occurrence of cytokine release. Therefore, in vitro cytokine release assays are best used for hazard identification and not for risk quantitation. With the current assays, it is not possible to define a threshold or exposure level in which cytokine release may be of concern, thus underlying the importance of a suitable in vivo model of stimulation.
Register for The Source℠ to access the Case Study documenting this comparison. Click here to log in or click here to register.
The following resources are available in the Source℠. Click here to register.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
The development of reliable inflammatory markers and in vitro assays capable of predicting in vivo cytokine release could help reduce study costs and the number of animals used for toxicology studies.
We now offer several new evaluation methods that allow for the observation of decreases in platelet counts and/or alterations in platelet function in order to monitor the efficacy or potential undesired drug effects on platelets.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.